These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35985473)

  • 1. Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling.
    Marchianò S; Biagioli M; Roselli R; Zampella A; Di Giorgio C; Bordoni M; Bellini R; Urbani G; Morretta E; Monti MC; Distrutti E; Fiorucci S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Nov; 1867(11):159218. PubMed ID: 35985473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH.
    Marchianò S; Biagioli M; Morretta E; Di Giorgio C; Roselli R; Bordoni M; Bellini R; Urbani G; Massa C; Monti MC; Zampella A; Distrutti E; Fiorucci S
    Sci Rep; 2023 Jan; 13(1):1602. PubMed ID: 36709356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
    Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease.
    Marchianò S; Biagioli M; Bordoni M; Morretta E; Di Giorgio C; Vellecco V; Roselli R; Bellini R; Massa C; Cari L; Urbani G; Ricci P; Monti MC; Giordano A; Brancaleone V; Bucci M; Zampella A; Distrutti E; Cieri E; Cirino G; Fiorucci S
    J Am Heart Assoc; 2023 Dec; 12(23):e031241. PubMed ID: 37996988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
    Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
    Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling.
    Marchianò S; Biagioli M; Roselli R; Zampella A; Di Giorgio C; Bordoni M; Bellini R; Morretta E; Monti MC; Distrutti E; Fiorucci S
    FASEB J; 2022 Jan; 36(1):e22060. PubMed ID: 34862975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation.
    Carino A; Marchianò S; Biagioli M; Fiorucci C; Zampella A; Monti MC; Morretta E; Bordoni M; Di Giorgio C; Roselli R; Ricci P; Distrutti E; Fiorucci S
    Nutrients; 2019 May; 11(5):. PubMed ID: 31117231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis.
    Beraza N; Ofner-Ziegenfuss L; Ehedego H; Boekschoten M; Bischoff SC; Mueller M; Trauner M; Trautwein C
    Gut; 2011 Mar; 60(3):387-96. PubMed ID: 21115542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
    Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
    Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity.
    Mueller M; Thorell A; Claudel T; Jha P; Koefeler H; Lackner C; Hoesel B; Fauler G; Stojakovic T; Einarsson C; Marschall HU; Trauner M
    J Hepatol; 2015 Jun; 62(6):1398-404. PubMed ID: 25617503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders.
    Fiorucci S; Sepe V; Biagioli M; Fiorillo B; Rapacciuolo P; Distrutti E; Zampella A
    Biochem Pharmacol; 2023 Oct; 216():115776. PubMed ID: 37659739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A high-dose of ursodeoxycholic acid treatment alleviates liver inflammation by remodeling gut microbiota and bile acid profile in a mouse model of non-alcoholic steatohepatitis.
    Li H; Wang M; Chen P; Zhu M; Chen L
    Biomed Pharmacother; 2024 May; 174():116617. PubMed ID: 38643542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.
    Hu J; Hong W; Yao KN; Zhu XH; Chen ZY; Ye L
    World J Gastroenterol; 2019 Mar; 25(12):1492-1501. PubMed ID: 30948912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease.
    Steinacher D; Claudel T; Trauner M
    Dig Dis; 2017; 35(3):282-287. PubMed ID: 28249257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ursodesoxycholic acid is an FFA4 agonist and reduces hepatic steatosis via FFA4 signaling.
    Xu F; Wang J; Wang P; Hou T; Zhou H; Zhao Y; Wang J; Liu Y; Liang X
    Eur J Pharmacol; 2022 Feb; 917():174760. PubMed ID: 35033554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bile acids as regulators of hepatic lipid and glucose metabolism.
    Trauner M; Claudel T; Fickert P; Moustafa T; Wagner M
    Dig Dis; 2010; 28(1):220-4. PubMed ID: 20460915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1.
    Renga B; Cipriani S; Carino A; Simonetti M; Zampella A; Fiorucci S
    PLoS One; 2015; 10(11):e0141082. PubMed ID: 26539823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.
    Fickert P; Pollheimer MJ; Silbert D; Moustafa T; Halilbasic E; Krones E; Durchschein F; Thüringer A; Zollner G; Denk H; Trauner M
    J Hepatol; 2013 Jun; 58(6):1201-8. PubMed ID: 23369794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
    Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
    JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ursodeoxycholic Acid Suppresses Lipogenesis in Mouse Liver: Possible Role of the Decrease in β-Muricholic Acid, a Farnesoid X Receptor Antagonist.
    Fujita K; Iguchi Y; Une M; Watanabe S
    Lipids; 2017 Apr; 52(4):335-344. PubMed ID: 28315136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.